A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Administration of Secukinumab (AIN457) in Patients With Asthma Not Adequately Controlled With Inhaled Corticosteroids and Long Acting Beta-agonists

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 19 Nov 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 20 Sep 2013 Planned end date changed from 1 May 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top